An Epstein-Barr virus vaccine
Epstein-Barr virus (EBV) infection has been associated with infectious mononucleosis, human cancers, and, most recently, development of multiple sclerosis. Thus, a vaccine to prevent infection with EBV would be broadly beneficial for human health.
Here, Wei and colleagues developed and tested two bivalent EBV vaccines, which targeted three or four viral glycoproteins that mediate EBV cell entry into epithelial cells and B cells.
The nanoparticle vaccines, gH/gL+gp350D123 and gH/gL/gp42+gp350D123, elicited immune responses in mice, ferrets, and nonhuman primates. Passive transfer of serum from vaccinated mice into humanized mice also conferred protection against EBV, supporting further development of these bivalent nanoparticle vaccines.
